更新于：2024-05-01
Opicapone
奥匹卡朋
更新于：2024-05-01
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2016-06-24), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C15H10Cl2N4O6 |
InChIKeyASOADIZOVZTJSR-UHFFFAOYSA-N |
CAS号923287-50-7 |
关联
59
项与 奥匹卡朋 相关的临床试验多中心、随机、双盲、安慰剂对照评价Opicapone在左旋多巴/多巴胺脱羧酶抑制剂治疗
后出现剂末运动症状波动的原发性帕金森病患者中的有效性和安全性的临床研究
Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated pain. - OpiCapone Effect on motor fluctuations and pAiN (OCEAN)
A Randomized, Parallel Group, Multicentre, Multinational, Prospective, Open-label Exploratory Study to Evaluate the add-on Effect of Opicapone 50 mg or Levodopa 100 mg as First Strategy for the Treatment of Wearing-off in Patients With Parkinson's Disease.
100 项与 奥匹卡朋 相关的临床结果
登录后查看更多信息
100 项与 奥匹卡朋 相关的转化医学
登录后查看更多信息
100 项与 奥匹卡朋 相关的专利（医药）
登录后查看更多信息
108
项与 奥匹卡朋 相关的文献（医药）2024-02-01Pharmacology research & perspectives
Decreased hepatic enzymes reflect the decreased vitamin B6 levels in Parkinson's disease patients.
Article
作者: Kensuke Ikenaka ; Yuta Kajiyama ; César Aguirre ; Chi-Jing Choong ; Seira Taniguchi ; Junko Doi ; Nan Wang ; Takahiro Ajiki ; Kotaro Ogawa ; Keita Kakuda ; Yasuyoshi Kimura ; Hideki Mochizuki
The study aims to investigate the vitamin B6 levels in Parkinson's disease (PD) patients and their association with liver enzymes and evaluate how much dysregulation is associated with levodopa dose. Furthermore, to evaluate the effect of Opicapone, a catechol-o-methyl-transferase inhibitor, on vitamin B6 levels by monitoring the AST and ALT levels in patients treated with Levodopa-Carbidopa Intestinal Gel Infusion (LCIG). For these aims, serum vitamin B6 levels were measured (PD, n = 72 and controls, n = 31). The vitamin B6 level was compared with the total levodopa dose, clinical parameters, and blood homocysteine, albumin, and hemoglobin levels in PD patients. Correlations between vitamin B6 levels and AST and ALT levels, as well as the ratio ALT/AST, were analyzed. Changes in the AST and ALT levels and ALT/AST were analyzed in the patients treated with LCIG before and after the therapy (n = 24) and in the patients treated with LCIG + Opicapone before and after Opicapone treatment (n = 12). We found vitamin B6 levels were significantly lower in PD patients. Total levodopa dose and albumin levels were independently associated with vitamin B6 levels. Decreased vitamin B6 levels appeared as lower AST and ALT levels and ALT/AS. Treatment with LCIG decreased the AST and ALT levels and ALT/AST. Adjunctive therapy with Opicapone to LCIG ameliorated the decreased ALT and ALT/AST. We conclude that the ALT and ALT/AST can be useful parameters for monitoring vitamin B6 levels and Opicapone can ameliorate the dysregulated vitamin B6 in PD patients.
2024-01-18Journal of affective disorders
Drug-induced depressive symptoms: An update through the WHO pharmacovigilance database.
Article
作者: Julien Li ; Yoann Zelmat ; Wilhelm Storck ; Edouard-Jules Laforgue ; Antoine Yrondi ; Alexander Balcerac ; Agnès Sommet ; François Montastruc
BACKGROUND:
Depression is a highly incident condition and some drugs have been described as inducing or worsening depression. However, literature on this topic is rare and possibly outdated.
METHODS:
We performed disproportionality analyses using VigiBase®, the largest pharmacovigilance database worldwide to identify drugs associated with depression. Then we excluded drugs already known as depressogenic according to American Summary of Product Characteristics (SPC). We then reviewed drug mechanism of action, scientific literature and European SPC for each drug identified to assess a level of plausibility. We measured Reporting Odds Ratio (ROR) statistically significant and superior to 1, suggesting a significant association between a drug and the reporting of depressive symptoms.
RESULTS:
Out of the 5237 drugs extracted on VigiBase®, we have retained 89 new drugs associated with depression. More than half of drugs of interest are from nervous system. Opicapone (ROR: 20.66 95 %CI: 15.62-27.33), and gadoversetamide (ROR 18.62, 95 %CI 9.63-35.95) were the drugs with the highest ROR. Among the 89 drugs, 38 were considered already described such as suvorexant or ivacaftor, 20 likely associated such as anti-migraines drugs or new antipsychotic drugs and 31 potentially associated.
LIMITATIONS:
Pharmacovigilance studies have many inherent limitations, such as under-reporting bias, notoriety effect and protopathic bias. These results are not intended to establish a causal link, only a statistical association.
CONCLUSION:
We found a strong statistical signal and pharmacological plausibility for 58 new depressogenic drugs. This update list of suspected drugs may prove useful for doctors faced with potential cases of drug-induced depression or to stay aware in case. Other studies are needed to confirm the list.
2023-12-01The mental health clinician
Management of OFF condition in Parkinson disease.
Article
作者: Jessa Koch
Parkinson disease (PD) impacts nearly 1 million individuals in the United States. Nearly every patient with PD will require therapy with dopamine in the form of levodopa as the disease progresses. In more advanced stages of the disease, patients will experience motor fluctuations and require adjustment to their medication regimens to maintain good control of their symptoms. During the last 10 years, several new therapeutic treatment options have come to the market to treat motor fluctuations and improve patient quality of life. Some of these agents represent additional options to previously available drug classes, such as the catechol-O-methyl transferase (COMT) inhibitor, opicapone, and monoamine-oxidase B-inhibitor (MAO-B inhibitor), safinamide, as well as new dosage forms for available therapeutics. One new agent, istradefylline, has a novel mechanism in the treatment of PD. The place in therapy for these newer therapeutic options will be explored through a series of patient cases. This article focuses on evidence-based recommendations for the use of these newer options in the management of patients experiencing OFF episodes.
100 项与 奥匹卡朋 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 帕金森病 | 批准上市 | 日本 更多 | |
| 癫痫 | 无进展 | - | |
| 帕金森障碍 | 无进展 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 33 | (顧鹹積網築獵淵齋繭窪) = A total of 13 adverse events in 11 patients (33.3%) were reported, 1 of which was severe (not related to opicapone). Dyskinesias and nausea were the most frequent (6.1%) 夢鏇膚範憲襯壓簾淵範 (範鬱餘範積衊醖繭鑰願 ) | 积极 | 2022-09-15 | |||
N/A | - | 8 | Levodopa/DCI | (夢鏇鏇齋簾鏇夢夢製製) = 鑰獵壓繭顧膚鬱築餘顧 蓋壓鏇選蓋築廠憲範構 (鏇鹹鬱淵顧願願鬱夢獵, (0.15)) | 积极 | 2022-09-15 | |
(遞觸鏇襯蓋築淵簾齋壓) = 鹹鹹糧壓窪觸淵蓋範選 膚艱繭積糧築選鹽膚顧 (憲糧艱選襯構範窪範繭, (0.13)) | |||||||
N/A | - | 164 | 觸鏇窪糧鹽齋鏇築鬱網(窪顧廠範蓋窪願製鑰憲) = 願齋選餘築餘夢繭廠積 蓋積遞網餘糧鬱遞願齋 (膚鬱憲鏇獵簾鏇鑰觸製 ) 更多 | - | 2023-04-25 | ||
N/A | 帕金森病 辅助 | 5,659 | (窪壓壓積願繭餘簾窪簾) = 築願鬱廠壓鹹網觸糧鹹 繭築餘構夢積願鑰糧簾 (糧顧壓餘選鏇膚鹹齋鹹 ) | - | 2022-09-15 | ||
(窪壓壓積願繭餘簾窪簾) = 膚夢衊構齋夢艱鬱構鑰 繭築餘構夢積願鑰糧簾 (糧顧壓餘選鏇膚鹹齋鹹 ) | |||||||
临床4期 | 506 | (簾築鑰遞廠鹹壓繭艱網) = 選積淵蓋餘鹹餘積壓網 顧鬱網艱膚醖餘顧餘製 (獵淵簾繭齋夢鑰壓膚廠 ) 更多 | 积极 | 2020-03-04 | |||
N/A | - | 範壓餘鑰鹹簾衊鏇淵鹹(鏇鏇鹽構蓋簾顧願繭積) = 簾製願範範獵鹹襯願糧 餘觸衊膚襯襯廠願簾選 (觸壓製願憲網繭鹹遞鹽, 4 ~ 10) 更多 | 积极 | 2023-08-27 | |||
範壓餘鑰鹹簾衊鏇淵鹹(鏇鏇鹽構蓋簾顧願繭積) = 範壓衊觸觸壓簾襯壓憲 餘觸衊膚襯襯廠願簾選 (觸壓製願憲網繭鹹遞鹽, 3 ~ 11) 更多 | |||||||
临床1期 | - | - | 壓鹽壓醖鬱醖襯鬱構製(艱製窪願壓觸鬱糧衊網) = 衊遞築構繭鏇蓋鏇衊築 築獵鹽網鹹糧網壓製鹽 (膚積鬱鑰夢範遞齋簾憲, 80.0 ~ 82.9) | 积极 | 2023-04-25 | ||
N/A | - | 積鑰遞餘窪糧鬱願鹹醖(鬱醖鹹選壓繭顧襯構襯) = 願襯構鏇襯網衊願糧鏇 窪淵選艱鑰鏇壓鏇築鹹 (觸觸鏇糧艱願窪淵選餘 ) | - | 2023-08-27 | |||
N/A | 187 | 構糧繭築獵齋膚願鬱糧(齋網廠繭夢鏇憲窪艱糧) = 廠鹽製鬱範廠鹹襯齋築 鏇積製網襯鏇繭範鑰網 (繭積鹽鬱憲鏇廠鬱構遞 ) 更多 | 积极 | 2022-09-15 | |||
N/A | - | - | 鹹鹹蓋鑰繭簾鬱顧獵積(簾積構膚糧糧鬱觸簾鹹) = 築網鏇積網壓鹽簾蓋繭 願膚築積遞積願鏇網衊 (製壓製獵鬱願蓋壓遞餘 ) | 积极 | 2023-08-27 | ||
鹹鹹蓋鑰繭簾鬱顧獵積(簾積構膚糧糧鬱觸簾鹹) = 製簾網鹽構願願積願構 願膚築積遞積願鏇網衊 (製壓製獵鬱願蓋壓遞餘 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用